Investigação da atividade Anti-inflamatória do extrato etanólico das folhas da Alpinia zerumbet (Pers.) B.L.Burtt &R.M.Sm

• Autor(a) principal: Bastos, Jéssica Lima
• Data de Publicação: 2017
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFS
• Texto Completo: http://ri.ufs.br/jspui/handle/riufs/7456
• topic: Plantas medicinais; Alpinia; Agentes anti-inflamatórios; Medicinal plants; Alpinia zerumbet; Anti-inflammatory

Introduction: Medicinal plants are an important source of new drugs, since it is an age-old practice preserved for several generations. They are used with the purpose of replacing or assisting conventional therapies in the treatment of various diseases. Among the various plants used by population for medicinal purposes, there is Alpinia zerumbet, popularly known as colônia, água-de-alevante, paco-seroca, cuité-açu and pacova; beingused in the treatment of heart problems and pain. Objective: The present study aimed to verify the anti-inflammatory action of the ethanolic extract of Alpinia zerumbet (EEAZ) in laboratory animals. Methods:Male Swiss mice (25-30 g; n = 6, per group) were treated with vehicle (saline + Tween 0.05%; v.o.), EEAZ (50, 100 or 200 mg/kg, v.o.;0.3, 1, 3 mg/ear; topically), morphine (3 mg/kg; i.p.), AAS (300 mg/kg; i.p.) or dexamethasone (2 mg/kg, i.p.; 0.05 mg/ear; topically). The formalin test (1%, 20 µL) in the paw, the carrageenan-induced peritonitis test (1%, 250 µL) and the TPA-induced ear edema (0.125 µg/µL) were performed. Results: In the first phase of formalin test, the dose of 100 mg/kg (56.6 ± 12.51; p <0.01) and 200 mg/kg (66.33 ± 4.12; p <0.05) decreased licking time (s) when compared to vehicle (112.83 ± 9.40) and morphine (39.33 ± 8.68). In the second phase, the highest doses had an effect: vehicle (118.66 ± 10.54), 100 mg/kg (15.4 ± 8.29; p <0.001), AAS 300 mg/kg (45.6 ± 13;p <0.001), 200 mg/kg (15.6 ± 5.80; p <0.001), morphine (16.33 ± 7.66; p <0.001). In the peritonitis test, all doses decreased leukocyte numbers, 50 mg/kg (3.54 ± 0.81; p <0.001), 100 mg/kg (5.48 ± 0.67; p <0.01) and 200 mg/kg (4.56 ± 0.88; p <0.001), when compared to the pretreated vehicle group (11.24 ± 1.32). The same was observed for dexamethasone (3.02 ± 0.97; p <0.001). When the topical effect of EEAZ was verified on the ear edema test, all tested concentrations reduced ear weight (0.33 ± 0.04, 0.29 ± 0.03, 24 ± 0.01; p <0.001) when compared to the control group (0.55 ± 0.05). The same was observed with myeloperoxidase activity (96.93 ± 17.67, 64.69 ± 9.79, 49.46 ± 11.01; p <0.01) in relation to the negative control group (130.61 ± 0.76). Conclusion: The EEAZ demonstrated systemic and topical anti-inflammatory activity in experimental models, thus demonstrating a therapeutic potential.